Tumor-node-metastasis staging of pancreatic adenocarcinoma

CA Cancer Journal for Clinicians

Volumn 58, Issue 2, 2008, Pages 111-125

  Katz, Matthew H G ^a   Hwang, Rosa ^a   Fleming, Jason B ^a   Evans, Douglas B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PORTAL VEIN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SUPERIOR MESENTERIC ARTERY; TUMOR LOCALIZATION; TUMOR VOLUME;

ADENOCARCINOMA; ALGORITHMS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 42049114228     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/CA.2007.0012     Document Type: Review

References (72)

1. Greene FL, Page DL, Fleming ID, et al. Exocrine pancreas, in Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
2. Merkel S, Mansmann U, Meyer T, et al. Confusion by frequent changes in staging of exocrine pancreatic carcinoma. Pancreas 2004;29:171-178.
3. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8:935-949.
4. Benassai G, Mastrorilli M, Quarto G, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 2000;73:212-218.
5. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68-72.
6. Kedra B, Popiela T, Sierzega M, Precht A. Prognostic factors of long-term survival after resective procedures for pancreatic cancer. Hepatogastroenterology 2001;48:1762-1766.
7. Kuhlmann KF, de Castro SM, Wesseling JG, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004;40:549-558.
8. Millikan KW, Deziel DJ, Silverstein JC, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999;65:618-623.
9. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995;221:59-66.
10. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg 1996;83:625-631.
11. Wenger FA, Peter F, Zieren J, et al. Prognosis factors in carcinoma of the head of the pancreas. Dig Surg 2000;17:29-35.
12. Willett CG, Lewandrowski K, Warshaw AL, et al. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993;217:144-148.
13. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199-1210.
14. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13:1035-1046.
15. Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997;168:1439-1443.
16. Nagakawa T, Mori K, Nakano T, et al. Perineural invasion of carcinoma of the pancreas and biliary tract. Br J Surg 1993;80:619-621.
17. Nagakawa T, Kayahara M, Ohta T, et al. Patterns of neural and plexus invasion of human pancreatic cancer and experimental cancer. Int J Pancreatol 1991;10:113-119.
18. Kayahara M, Nagakawa T, Konishi I, et al. Clinicopathological study of pancreatic carcinoma with particular reference to the invasion of the extrapancreatic neural plexus. Int J Pancreatol 1991;10:105-111.
19. Takahashi S, Ogata Y, Tsuzuki T. Combined resection of the pancreas and portal vein for pancreatic cancer. Br J Surg 1994;81:1190-1193.
20. Bold RJ, Charnsangavej C, Cleary KR, et al. Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg 1999;3:233-243.
21. Capussotti L, Massucco P, Ribero D, et al. Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy. Arch Surg 2003;138:1316-1322.
22. Howard TJ, Villanustre N, Moore SA, et al. Efficacy of venous reconstruction in patients with adenocarcinoma of the pancreatic head. J Gastrointest Surg 2003;7:1089-1095.
23. Jaeck D, Bachellier P, Oussoultzoglou E, et al. Analysis of a series of 100 mesenterico-portal vein resections during pancreatic resection [in French]. Bull Acad Natl Med 2006;190:1495-1506.
24. Wolff R, Abruzzesse J, Evans D. Neoplasms of the exocrine pancreas, in Kufe D, Pollock R, Weichselbaum R, eds. Holland-Frei Cancer Medicine. Vol. 2. Ontario, Canada: BC Decker; 2003:1585-1614.
25. Hartel M, Niedergethmann M, Farag-Soliman M, et al. Benefit of venous resection for ductal adenocarcinoma of the pancreatic head. Eur J Surg 2002;168:707-712.
26. Launois B, Franci J, Bardaxoglou E, et al. Total pancreatectomy for ductal adenocarcinoma of the pancreas with special reference to resection of the portal vein and multicentric cancer. World J Surg 1993;17:122-126.
27. Riediger H, Makowiec F, Fischer E, et al. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg 2006;10:1106-1115.
28. Roder JD, Stein HJ, Siewert JR. Carcinoma of the periampullary region: who benefits from portal vein resection? Am J Surg 1996;171:170-174.
29. Sindelar WF. Clinical experience with regional pancreatectomy for adenocarcinoma of the pancreas. Arch Surg 1989;124:127-132.
30. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990;211:447-458.
31. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721-731.
32. Bachellier P, Nakano H, Oussoultzoglou PD, et al. Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile? Am J Surg 2001;182:120-129.
33. Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg 1996;224:342-347.
34. van Geenen RC, ten Kate FJ, de Wit LT, et al. Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy. Surgery 2001;129:158-163.
35. Koniaris LG, Staveley-O'Carroll KF, Zeh HJ, et al. Pancreaticoduodenectomy in the presence of superior mesenteric venous obstruction. J Gastrointest Surg 2005;9:915-921.
36. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. In press.
37. Evans DB, TA R. Cancer of the pancreas, in DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott-Raven Publishers; 1997:1054-1087.
38. Gebhardt C, Meyer W, Reichel M, Wünsch PH. Prognostic factors in the operative treatment of ductal pancreatic carcinoma. Langenbecks Arch Surg 2000;385:14-20.
39. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003;237:74-85.
40. Takai S, Satoi S, Toyokawa H, et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas 2003;26:243-249.
41. Tsuchiya R, Noda T, Harada N, et al. Collective review of small carcinomas of the pancreas. Ann Surg 1986;203:77-81.
42. Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991;161:120-124.
43. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007;246:52-60.
44. Delcore R, Rodriguez FJ, Forster J, et al. Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Am J Surg 1996;172:463-468.
45. Horton KM, Fishman EK. Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am 2002;40:1263-1272.
46. Diehl SJ, Lehmann KJ, Sadick M, et al. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 1998;206:373-378.
47. Bardales RH, Stelow EB, Mallery S, et al. Review of endoscopic ultrasound-guided fine-needle aspiration cytology. Diagn Cytopathol 2006;34:140-175.
48. Chen VK, Eloubeidi MA. Endoscopic ultrasound-guided fine needle aspiration is superior to lymph node echofeatures: a prospective evaluation of mediastinal and peri-intestinal lymphadenopathy. Am J Gastroenterol 2004;99:628-633.
49. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004;70:235-240.
50. Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007;141:610-618.
51. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758-768.
52. Nishimura Y, Hosotani R, Shibamoto Y, et al. External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications. Int J Radiat Oncol Biol Phys 1997;39:39-49.
53. Verbeke CS, Leitch D, Menon KV, et al. Redefining the R1 resection in pancreatic cancer. Br J Surg 2006;93:1232-1237.
54. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-579.
55. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 2007;110:738-744.
56. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7.
57. Terwee CB, Nieveen Van Dijkum EJ, Gouma DJ, et al. Pooling of prognostic studies in cancer of the pancreatic head and periampullary region: the Triple-P study. Triple-P study group. Eur J Surg 2000;166:706-712.
58. Engelken FJ, Bettschart V, Rahman MQ, et al. Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol 2003;29:368-373.
59. Ikeda M, Okada S, Tokuuye K, et al. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 2001;91:490-495.
60. Ishii H, Okada S, Nose H, et al. Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas 1996;12:267-271.
61. Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373-378.
62. Krishnan S, Rana V, Janjan NA, et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 2006;107:2589-2596.
63. Sezgin C, Karabulut B, Uslu R, et al. Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. Scand J Gastroenterol 2005;40:1486-1492.
64. Ueno H, Okada S, Okusaka T, Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000;59:296-301.
65. Gallagher SF, Zervos EE, Murr MM. Distal pancreatectomy, in Von Hoff DD, Evans DB, Hruban RH, eds. Pancreatic Cancer. Boston, MA: Jones and Bartlett; 2005.
66. Abdalla EK. Pancreaticoduodenectomy, in Von Hoff DD, Evans DB, Hruban RH, eds. Pancreatic Cancer. Boston, MA: Jones and Bartlett; 2005.
67. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621-633.
68. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.
69. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-782.
70. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210.
71. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001;8:123-132.
72. Wayne JD, Abdalla EK, Wolff RA, et al. Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist 2002;7:34-45.